• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Primary Care
CMECNE

Lyme Disease: Diagnosis and Treatment

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. List the early features of Lyme disease
2. Restate the first line therapy for adults with early localized or early disseminated Lyme disease

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Jan 25 2023, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Read Disclaimer & Fine Print

SUMMARY:

Lyme disease is a serious condition caused by spirochetal bacteria Borrelia burgdorferi sensu lato following a deer tick bite that requires treatment.  The following provides key points regarding diagnosis, treatment, prophylaxis and tick removal.

DIAGNOSING LYME DISEASE:

Early features (3 to 30 days after tick bite) to watch for include:

  • Erythema migrans
    • 70 to 80% of infected individuals
    • At site of tick bite approximately day 7 (range 3 to 30 days)
  • Fever, headache, and fatigue
  • Joint and muscle aches
  • Swollen lymph nodes

Late features (days to months after tick bite)

    • Severe headaches and neck stiffness
    • Additional Erythema migrans rashes on other areas of the body
    • Arthritis with severe joint pain and swelling, particularly the knees and other large joints
    • Facial palsy (cranial neuritis)
    • Intermittent pain in tendons, muscles, joints, and bones
    • Heart palpitations or an irregular heart beat (Lyme carditis)
    • Episodes of dizziness or shortness of breath
    • Lyme meningitis or encephalitis
    • Nerve pain (radiculoneuritis)
  • Problems with short-term memory

Testing

Note: The CDC has updated the Lyme laboratory screening algorithm

  • CDC still recommends the two step approach
    • Step 1: Serologic testing using a sensitive enzyme immunoassay (EIA) or immunofluorescence assay
    • Step 2: Follow step one with a western immunoblot assay for specimens yielding positive or equivocal results
  • Modified two-step approach
    • Two enzyme immunoassays (EIA) are run concurrently or sequentially
    • The CDC states that

When cleared by FDA for this purpose, serologic assays that utilize a second EIA in place of western immunoblot assay are acceptable alternatives for the serologic diagnosis of Lyme disease

KEY POINTS:

  • Two-tiered serologic testing is more sensitive the longer infection has been present
  • Myth that Lyme disease can become chronic and no longer detectable on lab testing

Treatment

  • First line therapy for adults with early localized or early disseminated Lyme disease associated with erythema migrans, in the absence of specific neurologic manifestations or advanced atrioventricular heart block:
    • Doxycycline: 100 mg twice per day for 14 days (range 10 – 21 days), or
    • Amoxicillin: 500 mg 3 times per day for 14 days (range 14 – 21 days), or
    • Cefuroxime axetil (500 mg twice per day) for 14 days (range 14 – 21 days)
  • For treatment of late Lyme disease including arthritis, the above regimen is advised for 28 days
  • For persistent symptoms, such as joint swelling, Lyme meningitis, Lyme carditis, and dosing for children, see IDSA guidance in “Learn More – Primary Sources” below
  • The CDC concurs with the following IDSA recommendation that advises strongly against the treatment of chronic Lyme disease (highest level of evidence ‘I’, based on randomized controlled trials) as overtreatment with unnecessary antibiotics may prove fatal (e.g. septic shock, C. difficile, paraspinal abscess and osteomyelitis):

There is no convincing biologic evidence for the existence of symptomatic chronic B. burgdorferi infection among patients after receipt of recommended treatment regimens for Lyme disease. Antibiotic therapy has not proven to be useful and is not recommended for patients with chronic (⩾6 months) subjective symptoms after recommended treatment regimens for Lyme disease.

Prophylaxis: Management of asymptomatic individuals following a tick bite

  • Routine use of antimicrobial prophylaxis or serologic testing is not recommended
  • A single dose of doxycycline may be offered to adult patients (200 mg dose) and to children ⩾8 years of age (4.4 mg/kg, up to a maximum dose of 200 mg) when all of the following are met:
    •  The attached tick can be reliably identified as an adult or nymphal I. scapularis deer tick that is estimated to have been attached for ⩾36 h on the basis of the degree of engorgement of the tick with blood or on certainty about the time of exposure to the tick
    • Prophylaxis can be started within 72 h of the time that the tick was removed
    • Ecologic information indicates that the local rate of infection of these ticks with B. burgdorferi is ⩾20% (generally occurs in parts of New England, in parts of the mid-Atlantic States, and in parts of Minnesota and Wisconsin)
    • Doxycycline is not contraindicated

Tick Removal

  • The risk of getting a tick-borne disease is small if the tick is removed soon after it becomes attached
    • Deer ticks must remain attached one to two days to transmit Lyme disease, and about one day for the other diseases
  • Use tweezers to grasp the tick close to its mouth
  • Gently and slowly pull the tick straight outward
  • To avoid contact with the bacteria, if present, do not squeeze the ticks’ body
  • Wash the area and apply an antiseptic to the bite
  • Watch for early signs and symptoms of Lyme disease

Lyme Disease and Pregnancy

  • The CDC states

Lyme disease acquired during pregnancy may lead to infection of the placenta and possible stillbirth; however, no negative effects on the fetus have been found when the mother receives appropriate antibiotic treatment. There are no reports of Lyme disease transmission from breast milk.

Note: Treatment in pregnancy is similar to that of nonpregnant adults, although certain antibiotics, such as doxycycline, should be avoided due to potential risk related to dental discoloration that is associated with the tetracycline class of drugs

Learn More – Primary Sources:

CDC MMWR: Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease — United States 

CDC: Lyme Disease Diagnosis, Treatment and Testing

Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease

Signs and Symptoms of Untreated Lyme Disease

Minnesota Department of Natural Resources: Deer Ticks

CDC: Lyme Disease Transmission

JAMA: Lyme Disease in 2018 – What Is New (and What Is Not)

FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses

CDC: Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease

BMJ State-of-the-Art Review: Lyme borreliosis: diagnosis and management 

Take a post-test and get CME credits

TAKE THE POST TEST

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More  »

image_pdfFavoriteLoadingFavorite

< Previous
All Primary Care Posts
Next >

Related ObG Topics:

Zika virus: transmission, symptoms and management
Zika Virus Disease: How to Counsel Your Patient About Prevention
CDC Guidance for Non-Pregnant Patients and Available Diagnostic Tests for Zika Virus

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site